Sarepta Therapeutics Inc (NASDAQ:SRPT) – Equities research analysts at Leerink Swann issued their Q1 2018 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will earn ($0.45) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $66.00 target price on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2018 earnings at ($1.21) EPS and FY2019 earnings at $0.51 EPS.

Other equities research analysts have also issued reports about the company. BidaskClub lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Zacks Investment Research lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Robert W. Baird reissued an “outperform” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Finally, UBS Group reissued an “outperform” rating and issued a $56.51 price target (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $63.88.

Shares of Sarepta Therapeutics (SRPT) opened at $54.87 on Monday. The company has a market capitalization of $3,550.00, a price-to-earnings ratio of -26.90 and a beta of 1.37. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $59.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The company had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same period in the prior year, the firm earned ($0.95) earnings per share.

Several institutional investors have recently made changes to their positions in the company. Neuberger Berman Group LLC bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $1,134,000. California Public Employees Retirement System grew its stake in shares of Sarepta Therapeutics by 1.2% during the 3rd quarter. California Public Employees Retirement System now owns 142,900 shares of the biotechnology company’s stock worth $6,482,000 after acquiring an additional 1,700 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $474,000. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after acquiring an additional 2,493 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $922,000. 82.02% of the stock is owned by hedge funds and other institutional investors.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was purchased at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the transaction, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2018/01/08/q1-2018-earnings-estimate-for-sarepta-therapeutics-inc-srpt-issued-by-leerink-swann.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.